Drug intelligence / Profile preview

YHK803

Development stage: Unknown
Lead developer: Sichuan Provincial People's Hospital
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

YHK803 is a bispecific monoclonal antibody developed by Chengdu Yuanhengkang Biotech for the treatment of neovascular age-related macular degeneration (nAMD). It is designed to simultaneously neutralize vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), two synergistic drivers of pathological angiogenesis and vascular instability in the retina. By dual inhibition, YHK803 aims to improve visual outcomes and extend treatment durability compared to existing anti-VEGF monotherapies. The drug is administered via intravitreal injection and is currently undergoing a Phase 1 dose-escalation clinical trial (ChiCTR2500111581) to evaluate its safety, tolerability, and preliminary efficacy in patients with nAMD.

Other names: YHK803YHK-803YHK 803

Targets

ANGPT2 (Angiopoietin-2)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on YHK803.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YHK803.

Explore the full profile